



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/770,274	02/02/2004	Jean Francois Rossignol	3765-164	2226
30448	7590	06/29/2007		
AKERMAN SENTERFITT P.O. BOX 3188 WEST PALM BEACH, FL 33402-3188			EXAMINER HUI, SAN MING R	
			ART UNIT 1617	PAPER NUMBER
			MAIL DATE 06/29/2007	DELIVERY MODE PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Office Action Summary

Application No.

10/770,274

Applicant(s)

ROSSIGNOL, JEAN FRANCOIS

Examiner

San-ming Hui

Art Unit

1617

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☐ Responsive to communication(s) filed on ____.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-13 is/are pending in the application.
- 4a) Of the above claim(s) ____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) ____ is/are allowed.
- 6) ☒ Claim(s) 1-13 is/are rejected.
- 7) ☐ Claim(s) ____ is/are objected to.
- 8) ☐ Claim(s) ____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on ____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. ____.
 3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|--|---|
| 1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413) |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | Paper No(s)/Mail Date. ____ |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08) | 5) <input type="checkbox"/> Notice of Informal Patent Application |
| Paper No(s)/Mail Date ____ | 6) <input type="checkbox"/> Other: ____ |

DETAILED ACTION

Claim Rejections - 35 USC § 112

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Claims 1-11 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the enablement requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention. In the instant case, the specification does not provide sufficient information or guidance so that one of skilled in the art would practice the instant invention without undue experimentation.

Ex parte Forman (230 USPQ 546, BdPatApp & Int.) and *In re Wands* (858 F.2d 731, 8 USPQ2d 1400, 1404, Fed. Cir. 1988) provide several factors in determining whether the specification of an application allows the skilled artisan to practice the invention without undue experimentation. Having said factors in mind, the instant specification fails to reasonably provide enablement for methods of preventing the claimed condition. Specifically, the recitation of "prevention of one or more larval or adult stage helminthic infections in a human or an animal" in the instant claims 1 and 2, direct the claims to methods of preventing a pathological condition. However, the specification fails to properly enable such methods.

In the instant case, the burden of enabling for preventing one or more larval or adult stage helminthic infections requires appropriate screening testing, subsequent data compilation, and finally appropriate data analysis, to assess and properly enable one skill in the art whether one or more larval or adult stage helminthic infections are prevented in a patient. For example, the specification must provide adequate guidance whether one or more larval or adult stage helminthic infections can be prevented from forming in a patient or in this case, a mammal, once the composition is administered to a subject susceptible to have one or more larval or adult stage helminthic infections. Since infection is construed as simply the entry of a single microorganism into the host, it is quite difficult, if not possible, to prevent even one microorganism getting into the body of a human or animal.

Moreover, the specification must provide direct evidence associating the claimed prevention to the composition applied. The burden of showing preventative properties is greater than that of enabling a treatment, because one of ordinary skill in the art must not only show competent screening of those subjects susceptible to such conditions, but also show that the efficacy of a preventative method is directly caused by applying or administering the instantly claimed composition to the susceptible subjects.

In this case, there is no teachings for screening methods identifying susceptible subjects nor is there any direct evidence of efficacy establishing a preventative property associated with the claimed composition. Furthermore, the state of the prior art concerning methods of preventing one or more larval or adult

Art Unit: 1617

stage helminthic infections is not well described, nor does it provide for any absolute prevention. Accordingly, undue experimentation is necessary to determine screening and testing protocols to demonstrate the efficacy of the presently claimed invention.

Moreover, the instant recitation of "animals" encompass such group of animals such as cats, dogs, cows, horses, whales, etc.. Once again, the state of art concerning preventing one or more larval or adult stage helminthic infections for such animals are not well defined. Specification does not provide any working examples nor does it describe the in vivo correlation between all species of mammal the activity of the instant compounds. Accordingly, in order to practice the claimed invention commensurate in scope with the claims, one of ordinary skill in the art must perform undue experimentation to screen for susceptible mammals, test and demonstrate the efficacy of the compositions for preventative methods. Accordingly, specification does not provide adequate enablement under 35 U.S.C. 112, first paragraph.

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

Claims 1-13 are rejected under 35 U.S.C. 103(a) as being unpatentable over Keshmiri et al. (Eur. Respir. J., 1999 ;14 :503-507) and Stettler et al. (Antimicrobial agents and Chemotherapy, 2003;47(2):467-474).

Keshmiri et al. teaches albendazole as effective in treating *Echinococcus* infections (See the abstract). Keshmiri et al. teaches the dosage of albendazole as 800mg (See page 503, col. 2, last paragraph).

Stettler et al. teaches nitazoxanide as effective in battling against *Echinococcus multilocularis* metacestodes (See the abstract). Stettler teaches the concentration of nitazoxanide used as 10µg/ml (See The Materials and Methods Sections in page 468 and Figure 1).

The references do not expressly teach use of both albendazole and nitazoxanide together in a method of treating *Echinococcus* infection. The references do not expressly teach the herein claimed dosage of albendazole and nitazoxanide. The references do not expressly teach the method of increasing the serum albendazole sulfoxide levels.

It would have been obvious to one of ordinary skill in the art at the time of invention to use both albendazole and nitazoxanide together, in the dosage herein claimed, in a method of treating *Echinococcus* infection.

One of ordinary skill in the art would have been motivated to use both albendazole and nitazoxanide together, in the dosage herein claimed, in a method of treating *Echinococcus* infection. Since both albendazole and nitazoxanide are known to be useful in treating *Echinococcus* infection, concomitantly employ two agents in a single method treating the very same

Art Unit: 1617

purpose is *prima facie* obvious (see *In re Kerkhoven* 205 USPQ 1069 (CCPA 1980)). Furthermore, the optimization of result effect parameters (dosage range, dosing regimens) is obvious as being within the skill of the artisan.

It is noted that although the references does not teach the interaction or effect between albendazole and nitazoxanide, such interaction or effect, i.e., increasing the serum level of albendazole, would be considered present in the treatment method of *Echinococcus* when both albendazole and nitazoxanide employed together.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to San-ming Hui whose telephone number is (571) 272-0626. The examiner can normally be reached on Mon 9:00 to 1:00, Tu - Fri from 9:00 to 6:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Sreeni Padmanabhan, PhD., can be reached on (571) 272-0629. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Art Unit: 1617

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.


San-ming Hui
Primary Examiner
Art Unit 1617